Last 19 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -3.88 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 3.81 | 3.80 | 3.08 | 4.86 | 3.46 | 0.71 | 0.56 | 1.02 | 2.08 | 1.52 | 1.62 | 2.76 | 3.61 | 3.08 | 14.00 | — | — | — | — | — |
| — | +433.4% | +453.3% | +376.3% | +66.5% | -53.3% | -65.8% | -63.1% | -42.6% | -50.5% | -88.4% | — | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -52.5% | -12.7% | -15.2% | -15.6% | -14.0% | -11.0% | -11.2% | -5.5% | -12.1% | -8.4% | -10.1% | -10.3% | -9.3% | -52.7% | -67.7% | — | — | 0.2% | 0.6% | 4.5% |
| — | -15.4% | -35.8% | -185.5% | -16.0% | -31.3% | -11.2% | +46.7% | -29.2% | +84.1% | +85.1% | — | — | -21904.3% | -10836.7% | — | — | — | — | — | |
| ROA | -46.8% | -11.9% | -14.1% | -13.3% | -12.0% | -9.7% | -9.9% | -4.9% | -10.9% | -7.4% | -8.1% | -8.2% | -7.6% | -43.1% | -38.7% | -20.5% | -18.0% | 0.2% | 0.6% | 4.1% |
| — | -22.9% | -42.7% | -171.3% | -9.3% | -31.2% | -22.4% | +40.5% | -44.1% | +82.9% | +79.1% | +59.8% | +57.7% | -21292.0% | -6763.0% | -599.2% | — | — | — | — | |
| ROIC | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -0.5% | -0.3% | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 9.05 | 12.90 | 19.33 | 9.05 | 5.58 | 8.40 | 8.14 | 9.16 | 10.36 | 12.57 | 6.17 | 4.97 | 6.15 | 5.68 | 8.89 | 1.48 | 3.68 | 121.03 | 4.23 | 11.47 |
| — | +53.6% | +137.4% | -1.2% | -46.1% | -33.2% | +32.0% | +84.4% | +68.5% | +121.2% | -30.6% | +234.6% | +66.9% | -95.3% | +110.1% | -87.1% | — | — | — | — | |
| Quick Ratio | 9.05 | 12.90 | 19.33 | 9.05 | 5.58 | 8.40 | 8.14 | 9.16 | 10.36 | 12.57 | 6.17 | 4.97 | 6.15 | 5.68 | 8.89 | 1.48 | 3.68 | 121.03 | 4.23 | 11.47 |
| — | +53.6% | +137.4% | -1.2% | -46.1% | -33.2% | +32.0% | +84.4% | +68.5% | +121.2% | -30.6% | +234.6% | +66.9% | -95.3% | +110.1% | -87.1% | — | — | — | — | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 19 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ZURA stock.
Zura Bio Limited's current P/E is -3.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Zura Bio Limited's business trajectory between earnings reports.